Jessica Bate
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jessica Bate has a total of 177 co-authors. Here are the top co-authors by number of shared publications:
- Paul Trafford Heath
Centre for Neonatal and Paediatric Infection and Vaccine Institute, City St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK
8 shared publications Julia Chisholm
Paediatric & TYA Oncology, Royal Marsden Hospital, London, UK
6 shared publications- Judith Breuer
University College London, London, UK
4 shared publications - Mary Ramsay
Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK
4 shared publications Bob Phillips
Centre for Reviews and Dissemination, University of York, York, UK
3 shared publicationsClaire Cuerden
Paediatric Oncology, Southampton Children’s Hospital, Southampton, UK
3 shared publications
Latest Publications
- Open Access
- 20 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (2) , e70013
A National Audit of Current UK Practice on the Use of Anti‐Emetics for Chemotherapy‐Induced Nausea and Vomiting in Children
This UK national audit aimed to assess adherence to evidence‐based chemotherapy‐induced nausea and vomiting (CINV) guidelines for children with cancer, which emphasise treatment emetogenicity assessment, symptom monitoring and appropriate antiemetic use. Data from 99 inpatient episodes in 12 centres were collected over 5 days in January 2024 via an anonymised survey. Concordance with 2018 CCLG guidelines was 83%, with 6% of cases overestimated and 11% underestimated levels of emetogenicity. This first UK national audit demonstrates generally good alignment with guidelines. Future audits should include prescribing practices in outpatient and ambulatory settings to provide a more comprehensive evaluation of CINV management.
- 20 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (2) , e70013
Open AccessA National Audit of Current UK Practice on the Use of Anti‐Emetics for Chemotherapy‐Induced Nausea and Vomiting in Children
This UK national audit aimed to assess adherence to evidence‐based chemotherapy‐induced nausea and vomiting (CINV) guidelines for children with cancer, which emphasise treatment emetogenicity assessment, symptom monitoring and appropriate antiemetic use. Data from 99 inpatient episodes in 12 centres were collected over 5 days in January 2024 via an anonymised survey. Concordance with 2018 CCLG guidelines was 83%, with 6% of cases overestimated and 11% underestimated levels of emetogenicity. This first UK national audit demonstrates generally good alignment with guidelines. Future audits should include prescribing practices in outpatient and ambulatory settings to provide a more comprehensive evaluation of CINV management.
- 1 October 2025
- Published by BMJ in Archives of Disease in Childhood
- Vol. 111 (2) , 141-146
Seroprevalence of measles antibodies in children with cancer: results of a 2024 UK service evaluation
Objective To assess measles seroprevalence and testing practices in children with cancer in the UK. Design Multicentre evaluation of measles serology data for children on active treatment for cancer between January and March (Q1) 2024. Setting Eleven UK paediatric oncology centres (eight principal treatment centres and three shared care units). Patients Children aged Results A total of 695 eligible patients were included with a median age of 5.2 years (IQR 3.3–10.8 years). Baseline measles serology was tested in 545 patients with 89.0% positive for IgG antibodies. Cross-sectional testing of patients in Q1 2024 was undertaken in 289 patients with 78.5% measles seropositivity. Of the 121 patients tested at both time points who were measles seropositive at diagnosis, 23 (19.0%) were seronegative at retest. Most patients who lost pre-existing humoral immunity had an underlying diagnosis of leukaemia (n=16) followed by non-solid central nervous system (CNS) tumour (n=3), CNS tumour (n=2), lymphoma (n=1) and other (n=1). Although the odds of losing immunity were higher in haematological malignancy groups, this was not statistically significant (OR=1.44, 95% CI 0.52 to 3.99). Conclusions Children with cancer can lose pre-existing humoral immunity to measles during treatment. Variability in testing practices and rising measles cases nationally requires a standardised approach. Retesting measles serostatus during national outbreaks is important to identify susceptible patients who may require postexposure intravenous immunoglobulin.
- 1 October 2025
- Published by BMJ in Archives of Disease in Childhood
- Vol. 111 (2) , 141-146
Seroprevalence of measles antibodies in children with cancer: results of a 2024 UK service evaluation
Objective To assess measles seroprevalence and testing practices in children with cancer in the UK. Design Multicentre evaluation of measles serology data for children on active treatment for cancer between January and March (Q1) 2024. Setting Eleven UK paediatric oncology centres (eight principal treatment centres and three shared care units). Patients Children aged Results A total of 695 eligible patients were included with a median age of 5.2 years (IQR 3.3–10.8 years). Baseline measles serology was tested in 545 patients with 89.0% positive for IgG antibodies. Cross-sectional testing of patients in Q1 2024 was undertaken in 289 patients with 78.5% measles seropositivity. Of the 121 patients tested at both time points who were measles seropositive at diagnosis, 23 (19.0%) were seronegative at retest. Most patients who lost pre-existing humoral immunity had an underlying diagnosis of leukaemia (n=16) followed by non-solid central nervous system (CNS) tumour (n=3), CNS tumour (n=2), lymphoma (n=1) and other (n=1). Although the odds of losing immunity were higher in haematological malignancy groups, this was not statistically significant (OR=1.44, 95% CI 0.52 to 3.99). Conclusions Children with cancer can lose pre-existing humoral immunity to measles during treatment. Variability in testing practices and rising measles cases nationally requires a standardised approach. Retesting measles serostatus during national outbreaks is important to identify susceptible patients who may require postexposure intravenous immunoglobulin.
Ethnicity and childhood cancer survival
We need high quality data to analyse outcomes
- 16 February 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (5) , e31595
MEK Inhibition With Trametinib for the treatment of MAP2K1‐Mutated Rosai–Dorfman–Destombes Disease Arising from the Nasopharynx in a Paediatric Patient
- 16 February 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (5) , e31595
MEK Inhibition With Trametinib for the treatment of MAP2K1‐Mutated Rosai–Dorfman–Destombes Disease Arising from the Nasopharynx in a Paediatric Patient
- 30 January 2024
- Published by BMJ in Archives of Disease in Childhood
- Vol. 109 (4) , 321-325
Patient and parent perspectives on paediatric cancer multidisciplinary team working and national advisory panels in the UK: a qualitative research study
Objective The concept of patient-centred care is central to the role of cancer multidisciplinary teams (MDTs) and particularly pertinent with the recent rise in number of virtual national advisory panels (NAPs) for childhood cancer in the UK. We sought to explore patient and caregiver views regarding MDT working and NAPs. Methods Three focus groups were undertaken between March 2019 and January 2020. Results Sixteen participants attended. All regarded MDTs and NAPs highly, while highlighting patient involvement in decision-making should not be diluted by this process. The importance of personalised consultations was stressed, acknowledging that information-sharing preferences may change with circumstance and time. Most participants felt they had not been actively involved in decisions, including those made following MDT or NAP discussions. Group suggestions to improve patient-centred care included a clinician knowing them presenting their case, referral proformas to include family-related factors and an advocate attending meetings to represent the patient/family view. Conclusion Several changes have been driven forward by this work, including the modification of NAP referral proformas to include additional information. Patient and parent perspectives are now embedded into a best practice model for the NAPs to promote personalised recommendations at national level.
- 30 January 2024
- Published by BMJ in Archives of Disease in Childhood
- Vol. 109 (4) , 321-325
Patient and parent perspectives on paediatric cancer multidisciplinary team working and national advisory panels in the UK: a qualitative research study
Objective The concept of patient-centred care is central to the role of cancer multidisciplinary teams (MDTs) and particularly pertinent with the recent rise in number of virtual national advisory panels (NAPs) for childhood cancer in the UK. We sought to explore patient and caregiver views regarding MDT working and NAPs. Methods Three focus groups were undertaken between March 2019 and January 2020. Results Sixteen participants attended. All regarded MDTs and NAPs highly, while highlighting patient involvement in decision-making should not be diluted by this process. The importance of personalised consultations was stressed, acknowledging that information-sharing preferences may change with circumstance and time. Most participants felt they had not been actively involved in decisions, including those made following MDT or NAP discussions. Group suggestions to improve patient-centred care included a clinician knowing them presenting their case, referral proformas to include family-related factors and an advocate attending meetings to represent the patient/family view. Conclusion Several changes have been driven forward by this work, including the modification of NAP referral proformas to include additional information. Patient and parent perspectives are now embedded into a best practice model for the NAPs to promote personalised recommendations at national level.
- 10 January 2024
- Published by BMJ in Archives of Disease in Childhood
- Vol. 109 (3) , 257-258
Variation in central venous catheter care and management: a review of UK paediatric oncology principal treatment centre practice
- 10 January 2024
- Published by BMJ in Archives of Disease in Childhood
- Vol. 109 (3) , 257-258
Variation in central venous catheter care and management: a review of UK paediatric oncology principal treatment centre practice
- Open Access
- 24 December 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (3) , e30159
National advisory panels for childhood cancer in the United Kingdom: An evaluation of current practice and a best practice statement for the future
Background: National advisory panels (NAPs) have been established for the care of children and young people (CYP) with cancer in the United Kingdom since 2011, with an increase in panel number in recent years. Their practice has not previously been reviewed; therefore, we sought to evaluate the role, practice and impact of six selected NAPs offering expertise in ependymoma, histiocytosis, leukaemia, neuroblastoma, renal tumours and sarcoma.Procedure: This service evaluation used mixed methodology, including review of NAP documentation, semi‐structured interviews with the NAP chairs and an analysis of the cases referred for discussion.Results: Total 1110 referrals were analysed. Results demonstrated the significant scope and amount of work undertaken by the NAPs, largely testament to the commitment of the panel members. Specific roles fulfilled have been highlighted, and NAP recommendations have been shown to influence clinical decision‐making and be implemented in the majority of cases. Despite widespread good practice, areas to address have been identified; these include clarity regarding NAP membership, consistency in recommendations, the consideration of holistic information to promote personalised management and the exploration of wider multidisciplinary team roles.Conclusions: In the context of increasing demand and the escalating number of NAPs, it is timely to consider how service improvement can be facilitated. Best practice guidelines have been formulated as a product of this study, to promote a sustainable and effective model for NAPs. Review and benchmarking national panel performance against these guidelines will drive high standards of care going forward and they should be embedded as standard practice.
- 24 December 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (3) , e30159
Open AccessNational advisory panels for childhood cancer in the United Kingdom: An evaluation of current practice and a best practice statement for the future
Background: National advisory panels (NAPs) have been established for the care of children and young people (CYP) with cancer in the United Kingdom since 2011, with an increase in panel number in recent years. Their practice has not previously been reviewed; therefore, we sought to evaluate the role, practice and impact of six selected NAPs offering expertise in ependymoma, histiocytosis, leukaemia, neuroblastoma, renal tumours and sarcoma.Procedure: This service evaluation used mixed methodology, including review of NAP documentation, semi‐structured interviews with the NAP chairs and an analysis of the cases referred for discussion.Results: Total 1110 referrals were analysed. Results demonstrated the significant scope and amount of work undertaken by the NAPs, largely testament to the commitment of the panel members. Specific roles fulfilled have been highlighted, and NAP recommendations have been shown to influence clinical decision‐making and be implemented in the majority of cases. Despite widespread good practice, areas to address have been identified; these include clarity regarding NAP membership, consistency in recommendations, the consideration of holistic information to promote personalised management and the exploration of wider multidisciplinary team roles.Conclusions: In the context of increasing demand and the escalating number of NAPs, it is timely to consider how service improvement can be facilitated. Best practice guidelines have been formulated as a product of this study, to promote a sustainable and effective model for NAPs. Review and benchmarking national panel performance against these guidelines will drive high standards of care going forward and they should be embedded as standard practice.
- Open Access
- 12 December 2022
- Published by BMJ in Archives of Disease in Childhood
- Vol. 108 (3) , 192-197
Can I go home now? The safety and efficacy of a new UK paediatric febrile neutropenia protocol for risk-stratified early discharge on oral antibiotics
Objective To evaluate a new protocol of risk stratification and early discharge for children with febrile neutropenia (FN). Design Prospective service evaluation from 17 April 2020 to 16 April 2021. Setting 13 specialist centres in the UK. Patients 405 children presenting with FN. Intervention All children received intravenous antibiotics at presentation. Risk stratification was determined using the Australian-UK-Swiss (AUS) rule and eligibility for homecare assessed using criteria including disease, chemotherapy, presenting features and social factors. Those eligible for homecare could be discharged on oral antibiotics after a period of observation proportional to their risk group. Main outcome measures Median duration of admission and of intravenous antibiotics, and percentage of patients with positive blood cultures, significant infection, readmission within 7 days of initial presentation, intensive care unit (ICU) admission, death from infection and death from other causes. Results 13 centres contributed 729 initial presentations of 405 patients. AUS rule scores were positively correlated with positive blood cultures, significant infection, ICU admission and death. 20% of children were eligible for homecare with oral antibiotics, of which 55% were low risk (AUS 0–1). 46% low-risk homecare eligible patients were discharged by 24 hours vs 2% homecare ineligible. Homecare readmission rates were 14% overall and 16% for low-risk cases (similar to a meta-analysis of previous studies). No child eligible for homecare was admitted to ICU or died. Conclusions Use of the AUS rule and homecare criteria allow for safe early outpatient management of children with FN.
- 12 December 2022
- Published by BMJ in Archives of Disease in Childhood
- Vol. 108 (3) , 192-197
Open AccessCan I go home now? The safety and efficacy of a new UK paediatric febrile neutropenia protocol for risk-stratified early discharge on oral antibiotics
Objective To evaluate a new protocol of risk stratification and early discharge for children with febrile neutropenia (FN). Design Prospective service evaluation from 17 April 2020 to 16 April 2021. Setting 13 specialist centres in the UK. Patients 405 children presenting with FN. Intervention All children received intravenous antibiotics at presentation. Risk stratification was determined using the Australian-UK-Swiss (AUS) rule and eligibility for homecare assessed using criteria including disease, chemotherapy, presenting features and social factors. Those eligible for homecare could be discharged on oral antibiotics after a period of observation proportional to their risk group. Main outcome measures Median duration of admission and of intravenous antibiotics, and percentage of patients with positive blood cultures, significant infection, readmission within 7 days of initial presentation, intensive care unit (ICU) admission, death from infection and death from other causes. Results 13 centres contributed 729 initial presentations of 405 patients. AUS rule scores were positively correlated with positive blood cultures, significant infection, ICU admission and death. 20% of children were eligible for homecare with oral antibiotics, of which 55% were low risk (AUS 0–1). 46% low-risk homecare eligible patients were discharged by 24 hours vs 2% homecare ineligible. Homecare readmission rates were 14% overall and 16% for low-risk cases (similar to a meta-analysis of previous studies). No child eligible for homecare was admitted to ICU or died. Conclusions Use of the AUS rule and homecare criteria allow for safe early outpatient management of children with FN.
- 16 September 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (12) , e29985
Answers to common questions about COVID‐19 vaccines in children with cancer
Background: The SARS‐CoV‐2 outbreak in 2020 evolved into a global pandemic, and COVID‐19 vaccines became rapidly available, including for pediatric patients. However, questions emerged that challenged vaccine acceptance and use. We aimed to answer these questions and give recommendations applicable for use in pediatric patients with cancer by healthcare professionals and the public.Methods: A 12‐member global COVID‐19 Vaccine in Pediatric Oncology Working Group made up of physicians and nurses from all world regions met weekly from March to July 2021. We used a modified Delphi method to select the top questions. The Working Group, in four‐member subgroups, answered assigned questions by providing brief recommendations, followed by a discussion of the rationale for each answer. All Working Group members voted on each recommendation using a scale of 1 to 10, 10 being complete agreement. A “pass” recommendation corresponded to an agreement ≥7.5.Results: We selected 15 questions from 173 suggested questions. Based on existing published information, we generated answers for each question as recommendations. The overall average agreement for the 24 recommendations was 9.5 (95% CI 9.4–9.6).Conclusion: Top COVID‐19 vaccine‐related questions could be answered using available information. Reports on COVID‐19 vaccination and related topics have been published at record speed, aided by available technology and the priority imposed by the pandemic; however, all efforts were made to incorporate emerging information throughout our project. Recommendations will be periodically updated on a dedicated website.
- 16 September 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (12) , e29985
Answers to common questions about COVID‐19 vaccines in children with cancer
Background: The SARS‐CoV‐2 outbreak in 2020 evolved into a global pandemic, and COVID‐19 vaccines became rapidly available, including for pediatric patients. However, questions emerged that challenged vaccine acceptance and use. We aimed to answer these questions and give recommendations applicable for use in pediatric patients with cancer by healthcare professionals and the public.Methods: A 12‐member global COVID‐19 Vaccine in Pediatric Oncology Working Group made up of physicians and nurses from all world regions met weekly from March to July 2021. We used a modified Delphi method to select the top questions. The Working Group, in four‐member subgroups, answered assigned questions by providing brief recommendations, followed by a discussion of the rationale for each answer. All Working Group members voted on each recommendation using a scale of 1 to 10, 10 being complete agreement. A “pass” recommendation corresponded to an agreement ≥7.5.Results: We selected 15 questions from 173 suggested questions. Based on existing published information, we generated answers for each question as recommendations. The overall average agreement for the 24 recommendations was 9.5 (95% CI 9.4–9.6).Conclusion: Top COVID‐19 vaccine‐related questions could be answered using available information. Reports on COVID‐19 vaccination and related topics have been published at record speed, aided by available technology and the priority imposed by the pandemic; however, all efforts were made to incorporate emerging information throughout our project. Recommendations will be periodically updated on a dedicated website.
- 25 July 2022
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 40 (4) , 341-351
Global caregiver concerns of SARS-CoV-2 vaccination in children with cancer: a cross-sectional mixed-methods study
The objective of this study was to understand global caregiver concerns about SARS-CoV-2 vaccination for children with cancer and to provide healthcare providers with guidance to support parental decision-making. A co-designed cross-sectional mixed-methods survey was distributed to primary caregivers of children with cancer globally between April and May 2021 via several media. Caregivers were asked to rate the importance of vaccine-related questions and the median scores were ranked. Principal Component Analysis was conducted to identify underlying dimensions of caregiver concerns by World Bank income groups. Content analysis of free-text responses was conducted and triangulated with the quantitative findings. 627 caregivers from 22 countries responded to the survey with 5.3% (n = 67) responses from low-and-middle-income countries (LMIC). 184 caregivers (29%) provided free-text responses. Side effects and vaccine safety were caregivers’ primary concerns in all countries. Questions related to logistics were of concern for caregivers in LMIC. A small minority of caregivers (n = 17) did not consider the survey questions important; free-text analysis identified these parents as vaccine hesitant, some of them quoting safety and side effects as main reasons for hesitancy. Healthcare providers and other community organizations globally need to provide tailored information about vaccine safety and effectiveness in pediatric oncology settings. Importantly, continued efforts are imperative to reduce global inequities in logistical access to vaccines, particularly in LMIC.
- 25 July 2022
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 40 (4) , 341-351
Global caregiver concerns of SARS-CoV-2 vaccination in children with cancer: a cross-sectional mixed-methods study
The objective of this study was to understand global caregiver concerns about SARS-CoV-2 vaccination for children with cancer and to provide healthcare providers with guidance to support parental decision-making. A co-designed cross-sectional mixed-methods survey was distributed to primary caregivers of children with cancer globally between April and May 2021 via several media. Caregivers were asked to rate the importance of vaccine-related questions and the median scores were ranked. Principal Component Analysis was conducted to identify underlying dimensions of caregiver concerns by World Bank income groups. Content analysis of free-text responses was conducted and triangulated with the quantitative findings. 627 caregivers from 22 countries responded to the survey with 5.3% (n = 67) responses from low-and-middle-income countries (LMIC). 184 caregivers (29%) provided free-text responses. Side effects and vaccine safety were caregivers’ primary concerns in all countries. Questions related to logistics were of concern for caregivers in LMIC. A small minority of caregivers (n = 17) did not consider the survey questions important; free-text analysis identified these parents as vaccine hesitant, some of them quoting safety and side effects as main reasons for hesitancy. Healthcare providers and other community organizations globally need to provide tailored information about vaccine safety and effectiveness in pediatric oncology settings. Importantly, continued efforts are imperative to reduce global inequities in logistical access to vaccines, particularly in LMIC.